CompletedNCT01110317

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

Medication studyAges 18–65

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Study clarity

Study start dateJuly 2005

Recruitment status: Completed
Enrollment listed in the registry: 49
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 18 Years to 65 Years
Official registry ID: NCT01110317
Official title: Show the full official title
Open-Label, Parallel, Randomized, Multiple-Dose Pharmacokinetic Study of Paliperidone After Intramuscular Injection of Paliperidone Palmitate in the Deltoid or Gluteal Muscle in Subjects With Schizophrenia

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including paliperidone palmitate 100 mg.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.